SCHEMBL207144

SCHEMBL207144

COc1cccc(N2CCN(C(=O)CCC(=O)NC3CCC(Cc4cccc(C)c4)(N(C)C)CC3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
ADAMTS5 Q9UNA0 2/20 0.46
DRD4 P21917 1/20 0.44
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
LDHA P00338 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MMP13 P45452 1/20 0.41
ADAM17 P78536 1/20 0.41
GFER P55789 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206125 0.88 ADAMTS4 (0.47) ADAMTS4MTNR1AMTNR1BADAMTS5MEN1
SCHEMBL205941 0.88 MEN1 (0.42) ADAMTS5LMNAMEN1CYP3A4CYP2C9
SCHEMBL207062 0.87 KMT2A (0.47) ADAMTS5LMNAMEN1KMT2ATP53
SCHEMBL208523 0.84 SSTR1 (0.46) LMNAMEN1POLBCYP3A4CYP2C19
SCHEMBL209123 0.84 GFER (0.54) LMNAMEN1KMT2AMAPTGFER
SCHEMBL207068 0.82 USP2 (0.50) ADAMTS4ADAMTS5LMNAPOLBTP53
SCHEMBL205707 0.81 FAAH (0.49) LMNAMEN1KMT2AMAPTSSTR1
SCHEMBL208817 0.81 NPC1 (0.47) MEN1CYP3A4CYP2C9CYP2C19KMT2A
SCHEMBL205663 0.80 MEN1 (0.49) MEN1POLBKMT2ASIGMAR1
SCHEMBL205971 0.80 CXCR4 (0.46) DRD4MEN1KMT2ASIGMAR1SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD ADAMTS4 1239/4885MTNR1A 3152/4885MTNR1B 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.